We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Partnership Expands to Advance Novel Dual-Detection of Two Neglected Tropical Diseases

By LabMedica International staff writers
Posted on 08 Mar 2015
Print article
PATH (Seattle, WA, USA), a non-profit leader in global health equity, Signal Diagnostics (Seoul, Korea), a company of Alere Inc. (Waltham, MA, USA), and the [US] National Institute of Allergy and Infectious Diseases (NIAID) will collaborate on a rapid point-of-care combined test for both onchocerciasis (river blindness) and lymphatic filariasis (LF, elephantiasis), often co-endemic diseases.

The new biplex test will build on momentum of the current partnership between the three organizations to manufacture and distribute the recently launched Alere SD BIOLINE Onchocerciasis IgG4 rapid test. Their expanded partnership paves the way for PATH to transfer the technology to SD/Alere to manufacture and distribute the only antibody test for dual-detection of onchocerciasis and LF designed for use in rural and remote settings.

Of about 126 million at risk for river blindness, 99% live in Africa. Of about 1.39 billion at risk for LF, the vast majority live in Africa and in parts of Asia. Both commonly affect the same communities and cause great suffering, adding to the cycle of illness and poverty that impacts many remote areas of the world. The World Health Organization (WHO) has targeted both diseases for elimination by 2020. To stop transmission, control and elimination programs use the drug ivermectin, with a second drug added for LF. Accurate surveillance data are required to inform program decisions about stopping treatment of one or both drugs and detecting signs of reinfection.

The biplex test is based on detection of antibodies to parasite antigens Ov16 for onchocerciasis and Wb123 for LF. Both antigens were identified and characterized by scientists at NIAID. Field evaluations of the test will be conducted in the first half of 2015.

The dual-detection capability of the rapid Ov16/Wb123 test is designed to fill gaps in control programs in Africa where the diseases are co-endemic. Potential advantages include reduced cost, simplified use and logistics, and improved coordination of decision-making. The test can also be used to support disease elimination phase by monitoring post-control areas and detecting cases in low-prevalence areas.

“We are pleased to collaborate with PATH to develop another rapid test, this time for detecting onchocerciasis and lymphatic filariasis within one device,” said Byung-Ki Cho, vice president, Asia Pacific operations and R&D at SD/Alere, “The collaboration between SD/Alere, PATH, and NIAID will help eliminate and eradicate neglected tropical diseases.” “We are very happy to continue with SD/Alere as our commercialization partner for the new Ov16/Wb123 biplex rapid test,” said Tala de los Santos, director of diagnostics at PATH, “The new test bears great promise as a cost-effective diagnostic solution for supporting integrated surveillance activities.”

Related Links:

PATH
Alere


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.